Skip to main content

Table 3 Association of ACE gene D/I polymorphism with onset of clinical symptoms of patients in months considering the cohorts to CFTR mutation

From: The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis

Groups ACEgenotype ≤ 3 months > 3 months Total X2 p X2 p OR (CI 5-95%)
Without taking CFTR mutation into account I/I 38 28 66 0,880 0,644 0.012 0.9136 1.035 (0.555 - 1.931)
I/D 44 37 81 0.473 0.492 0.808 (0.4396 -1.484)
D/D 15 8 23 0.723 0.395 1.486 (0.5937, 3.721)
No identified CFTR mutation I/I 13 6 19 1,685 0,431 0.825 0.364 1.806 (0.5017 -6.498)
I/D 9 9 18 1.624 0.203 0.438 (0.122 - 1.576)
D/D 3 1 4 0.357 0.977 2.045 (0.194 - 21.58)
One CFTR mutation identified class I, II or III I/I 10 11 21 5,564 0,062 4.217 0.049 0.297 (0.084 – 0.995)
I/D 14 6 20 0.521 0.471 1.167 (0.775 – 1.757)
D/D 8 1 9 2.951 0.097 5,667 (0,647 – 49,61)
Two CFTR mutation identified class I, II and/or III I/I 15 11 26 0,599 1,026 0.773 0.379 1.527 (0.593 - 3.936)
I/D 21 22 43 0.122 0.727 0.854 (0.352 - 2.072)
D/D 4 6 10 0.511 0.704 0.611 (0.158 - 2.358)
  1. Values below 0.05 for p denote clinical correlation between variables. OR - odds ratio, CI- confidence interval, ≤ − less than or equal to, > − greater, D - deleted allele, I - insertion allele. No identified mutation (44 patients) – patients without of identified mutation in classes I, II or III. One identified mutation (51 patients) – patient with one identified mutation in class I, II, or III. Two identified mutation (85 patients) – patient with two mutations in class I, II or III.